Ignite Creation Date:
2024-05-05 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 9:51 AM
Study NCT ID:
NCT00698568
Status:
COMPLETED
Last Update Posted:
2008-06-17
First Post:
2008-06-16
Brief Title:
Safety Evaluation of Herpes Simplex Candidate Vaccine gD2t With Adjuvant in HSV Seropositive Seronegative Subjects
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Study to Evaluate the Safety of GSK Biologicals Herpes Simplex Candidate Vaccine gD2t With MPL in HSV Seropositive or Seronegative Subjects Without Genital Herpes Disease
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate versus a placebo the safety of Herpes simplex candidate vaccine with adjuvant in initially HSV seropositive or seronegative subjects who have no genital herpes disease
Detailed Description:
This study was monitored by a Data Safety Monitoring Board At the time of conduct of this study the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None